Related Experiment Videos
[Experimental studies on antitumor effects of lysozyme]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1982
Summary
Lysozyme (LY) alone showed limited antitumor effects but significantly enhanced chemotherapy against Meth-A and MH 134 tumors. Combination therapy with LY demonstrated potent inhibition of pulmonary metastases in Lewis lung carcinoma.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Context:
- Investigating the therapeutic potential of lysozyme (LY) in cancer treatment.
- Utilizing syngeneic tumor models (Meth-A, MH 134, Lewis lung carcinoma) in mice.
- Evaluating LY's efficacy alone and in combination with established chemotherapeutic agents.
Purpose:
- To determine the antitumor activity of lysozyme (LY) as a monotherapy.
- To assess the synergistic effects of LY combined with mitomycin C (MMC), bleomycin (BLM), and 5-fluorouracil (5-FU).
- To evaluate the impact of LY on pulmonary metastasis inhibition.
Summary:
- Lysozyme (LY) alone exhibited inhibitory effects on Meth-A tumor growth and Sarcoma-180 but showed no significant effect on MH 134 tumors.
- LY markedly enhanced the antitumor efficacy of MMC, BLM, and 5-FU against Meth-A and MH 134 tumors.
- Combination treatments of LY with MMC or 5-FU significantly inhibited pulmonary metastases in the Lewis lung carcinoma (3LL) model.
Impact:
- Lysozyme demonstrates potential as an adjuvant therapy to augment the effectiveness of conventional chemotherapy.
- Combination strategies involving lysozyme may offer improved outcomes for managing primary tumors and preventing metastasis.
- Further research into lysozyme's immunomodulatory or sensitizing mechanisms could reveal novel therapeutic applications in oncology.